 |
 |
 |
 |
 |
 |
 |
|
|||||||
|
|
SELECT PUBLICATIONS Carter HB et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267(16):2215-20. Abstract Chen Y et al. Contemporary experience with hormone refractory prostate cancer (HRPC-Stage D3) in the PSA-era: Report from the DOD CPDR National Database. Proc AUA 2004;Abstract 446. D’Amico AV et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004;172(5 Pt 2):42-6. Abstract Freedland SJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9. Abstract Loeb S et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006;67(2):316-20. Abstract Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7. Abstract Stamey TA et al. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004;172(4 Pt 1):1297-301. Abstract Tewari A et al. Robotic prostatectomy: A pooled analysis of published literature. Expert Rev Anticancer Ther 2006;6(1):11-20. Abstract
|
Editor Meet The Professors Case 1: from the practice of Case 2: from the practice of Case 3: from the practice of Richard Davi, MD Case 4: from the practice of Dr Nieder Case 5: from the practice of Benjamin M Tripp, MD INTERVIEWS Judd W Moul, MD Daniel P Petrylak, MD
|
 |
 |
